Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Search Results

Showing Results for transfusion-dependent anaemia

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Prof. Pierre Fenaux, Head of the Department of  Hematology and Immunology at Assistance Publique-Hôpitaux de Paris Nord (Hôpitaux Saint-Louis, R Debré, Avicenne) is a leading expert in haematology with extensive experience in the treatment and management of myelodysplastic syndromes (MDS). In this interview, he discusses key considerations for first-line therapies in lower-risk MDS, the latest advances in treatment and the role of organizations like the European School of Hematology (ESH) in supporting haematologists.

Mark CompleteCompleted
BookmarkBookmarked

Key points Olutasidenib induces durable responses in patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutations in the phase I and II clinical trials. The side effects of olutasidenib are well known and ...

Mark CompleteCompleted
BookmarkBookmarked

Mutations of the β-globin gene (HBB) cause sickle cell disease and β-thalassaemia, collectively named the β-haemoglobinopathies. As mankind’s most common severe genetic diseases, where they are most prevalent, public health systems can be stressed.1–3 Asymptomatic heterozygous carriers are protected ...

Mark CompleteCompleted
BookmarkBookmarked

Chemotherapy-induced myelosuppression has long been considered a toxicity that limits the dose of cytotoxic agents, which contributes to significant morbidity and mortality.1 Sub-optimal dose intensity may decrease the efficacy of therapy, thereby compromising progression-free survival (PFS) and overall survival (OS) ...

Mark CompleteCompleted
BookmarkBookmarked
Sachi Singhal, Shaji K Kumar

Treatment options for myeloma have rapidly expanded in the past decade and, as with many cancers, the number of oral drug options has increased considerably. Given the more limited number of cancer hospitals, patients often must travel considerable distance to ...

Mark CompleteCompleted
BookmarkBookmarked
Richard J Kelly, Alexandra Pike, Daniel Payne

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, chronic haematological illness. The condition presents on a background of bone marrow failure, and affected individuals can experience an array of symptoms due to chronic haemolysis, as well as episodes of acute haemolysis ...

Mark CompleteCompleted
BookmarkBookmarked
Cemaleddin Ozturk, Sinem Civriz Bozdag

Allogeneic haematopoietic cell transplantation (allo-HCT) has a bi-faceted role in the treatment of haematopoietic malignancies. First, allo-HCT gives high-dose chemotherapy a chance to reduce the leukaemic burden; second, it allows graft-originated natural killer and T cells to initiate an adoptive ...

Mark CompleteCompleted
BookmarkBookmarked
Mohammad Ammad Ud Din, Faiz Anwer

The chronic anaemia of beta-thalassemia major (b-thal) results from defective erythropoiesis secondary to a genetic defect in haemoglobin synthesis.1 Consequently, patients with moderate-to-severe disease rely on blood transfusions to maintain an adequate level of haemoglobin.2 Over time, this causes an ...

Mark CompleteCompleted
BookmarkBookmarked

Beta-thalassaemia is a hereditary blood disorder arising from impaired synthesis of beta globin chains, and can result in a range of outcomes from asymptomatic carriers to severe anaemia.1 Symptomatic thalassaemia presents in around 1 in 100,000 people worldwide, and 1 in 10,000 in Europe.1 ...

Mark CompleteCompleted
BookmarkBookmarked

Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living ...

Mark CompleteCompleted
BookmarkBookmarked

Beta-thalassemia is a hereditary blood disease in which a defect in globin chain synthesis production leads to ineffective production of red blood cells (RBCs) and anaemia.1 Beta-thalassemia is common in the Mediterranean region, South-East Asia, the Indian subcontinent and the ...

Mark CompleteCompleted
BookmarkBookmarked

In myelodysplastic syndrome (MDS), iron overload (IOL) is the result of multiple red blood cell (RBC) transfusions and increased iron absorption. The cause for the latter is low hepcidin levels due to an ineffective erythropoiesis.1 Increased iron absorption contributes to ...

Mark CompleteCompleted
BookmarkBookmarked

Early diagnosis of rare haematological diseases Rare haematological diseases often present ‘in disguise’, with nonspecific symptoms such as pancytopaenia, decreased circulating levels of one or two cell subsets and splenomegaly. Gaucher disease (GD) provides an excellent paradigm when considering challenges ...

Mark CompleteCompleted
BookmarkBookmarked

Myelodysplastic Syndromes and 5q Deletion Myelodysplastic syndromes (MDS) are a group of rare blood disorders that occur as a result of abnormal development of blood cells within the bone marrow. MDS may progress to life-threatening failure of the bone marrow ...

Mark CompleteCompleted
BookmarkBookmarked

The myelodysplastic syndromes (MDS) are a heterogeneous group of haematological disorders characterised by ineffective haematopoiesis with associated cytopenias and a hypercellular bone marrow (BM) with dysplastic changes.1 Patients with MDS have a variable reduction in the production of normal red ...

Mark CompleteCompleted
BookmarkBookmarked

Phenotypic diversity within the β-thalassaemia syndromes has traditionally received considerable interest, with several molecular and environmental modifiers of disease severity so far described.1 Patients with transfusion-dependent β-thalassaemia major (TM) suffer the most severe form and show the highest mortality rates.1 ...

Mark CompleteCompleted
BookmarkBookmarked

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haematopoietic stem cell disorders that impair normal haematopoiesis, resulting in a variable number of cytopenias and a potential to evolve into acute myeloid leukaemia (AML).1 With a median age at diagnosis ...

Mark CompleteCompleted
BookmarkBookmarked

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that impair normal hematopoiesis, resulting in a variable number of cytopenias and a potential to evolve into acute myeloid leukaemia (AML).1 With a median age at diagnosis ...

Load More...
Close Popup